Double-Blind, Placebo-Controlled Trial of Octreotide Long-Acting Repeatable (LAR) in Thyroid-Associated Ophthalmopathy

Dickinson, A. Jane, Vaidya, Bijay, Miller, Margaret, Coulthard, Alan, Perros, Petris, Baister, Elizabeth, Andrews, Christopher D., Hesse, Lutz, Heverhagen, Johannes T., Heufelder, Armin E. and Kendall-Taylor, Pat (2004) Double-Blind, Placebo-Controlled Trial of Octreotide Long-Acting Repeatable (LAR) in Thyroid-Associated Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 89 12: 5910-5915. doi:10.1210/jc.2004-0697

Author Dickinson, A. Jane
Vaidya, Bijay
Miller, Margaret
Coulthard, Alan
Perros, Petris
Baister, Elizabeth
Andrews, Christopher D.
Hesse, Lutz
Heverhagen, Johannes T.
Heufelder, Armin E.
Kendall-Taylor, Pat
Title Double-Blind, Placebo-Controlled Trial of Octreotide Long-Acting Repeatable (LAR) in Thyroid-Associated Ophthalmopathy
Journal name Journal of Clinical Endocrinology and Metabolism   Check publisher's open access policy
ISSN 0021-972X
Publication date 2004-12
Sub-type Article (original research)
DOI 10.1210/jc.2004-0697
Volume 89
Issue 12
Start page 5910
End page 5915
Total pages 6
Place of publication Bethesda MD
Publisher Endocrine Society
Language eng
Subject 110320 Radiology and Organ Imaging
Abstract Several uncontrolled studies suggest octreotide is beneficial in thyroid-associated ophthalmopathy (TAO); however, the natural tendency of TAO to improve mandates randomized, controlled trials. We report results of a double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR). Fifty euthyroid patients (11 males, 39 females; age 22–74 yr, median 50 yr) with active TAO [clinical activity score (CAS) ≥3, NOSPECS (no signs or symptoms; only signs, no symptoms; signs only; proptosis; eye muscle involvement; corneal involvement; sight visual acuity reduction) 2a-5a] of median duration 0.9 yr received either 30 mg LAR or placebo every 4 wk for 16 wk; both groups then received 30 mg LAR for wk 16–32 and were followed up without treatment for a further 24 wk. Objective assessments included all individual parameters of TAO, CAS, and derived scores for soft tissue inflammation (STI) and ophthalmopathy index (OI). During wk 0–16 there was significant reduction in STI, subjective diplopia, and CAS in LAR-treated patients; STI and CAS were also reduced with placebo. The OI reduced by –1.12 in LAR (P = 0.0017) vs. –0.23 in placebo (P = 0.33), giving a barely significant treatment effect by Wilcoxon (P = 0.043), but analysis of covariance failed to confirm this (P = 0.16). During wk 16–32 there was no significant change in OI in either group. The overall results (wk 0–32) showed reduction in STI and CAS in both groups. In this double-blind, placebo-controlled trial, no significant therapeutic effect of octreotide LAR was seen in patients with moderately severe TAO. The improvements in both treated and placebo groups emphasize that the results of open studies must be viewed with caution.
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 42 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 60 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 02 Mar 2009, 14:17:30 EST by Maryanne Watson on behalf of School of Medicine